Audiological and electrophysiological alterations in HIV-infected individuals subjected or not to antiretroviral therapy

被引:5
|
作者
Matas, Carla Gentile [1 ]
Samelli, Alessandra Giannella [1 ]
Leite Magliaro, Fernanda Cristina [1 ]
Segurado, Aluisio [2 ]
机构
[1] Univ Sao Paulo, Fac Med, Dept Fisioterapia Fonoaudiol & Terapia Ocupac, Sao Paulo, SP, Brazil
[2] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Acquired immunodeficiency syndrome; Adults; Auditory evoked potentials; Hearing loss; HIV; HUMAN-IMMUNODEFICIENCY-VIRUS; HEARING-LOSS; AIDS; MANIFESTATIONS; OTOTOXICITY; IMPAIRMENT; POTENTIALS; DISEASE;
D O I
10.1016/j.bjorl.2017.07.003
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Introduction: The Human Immunodeficiency Virus (HIV) and infections related to it can affect multiple sites in the hearing system. The use of High Activity Anti-Retroviral Therapy (HAART) can cause side effects such as ototoxicity. Thus, no consistent patterns of hearing impairment in adults with Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome have been established, and the problems that affect the hearing system of this population warrant further research. Objectives: This study aimed to compare the audiological and electrophysiological data of Human Immunodeficiency Virus-positive patients with and without Acquired Immune Deficiency Syndrome, who were receiving High Activity Anti-Retroviral Therapy, to healthy individuals. Methods: It was a cross-sectional study conducted with 71 subjects (30-48 years old), divided into groups: Research Group I: 16 Human Immunodeficiency Virus-positive individuals without Acquired Immunodeficiency Syndrome (not receiving antiretroviral treatment); Research Group II: 25 Human Immunodeficiency Virus-positive individuals with Acquired Immunodeficiency Syndrome (receiving antiretroviral treatment); Control Group: 30 healthy subjects. All individuals were tested by pure-tone air conduction thresholds at 0.25-8 kHz, extended high frequencies at 9-20 kHz, electrophysiological tests (Auditory Brainstem Response, Middle Latency Responses, Cognitive Potential). Results: Research Group I and Research Group II had higher hearing thresholds in both conventional and high frequency audiometry when compared to the control group, prolonged latency of waves I, III, V and interpeak I-V in Auditory Brainstem Response and prolonged latency of P300 Cognitive Potential. Regarding Middle Latency Responses, there was a decrease in the amplitude of the Pa wave of Research Group II compared to the Research Group I. Conclusions: Both groups with Human Immunodeficiency Virus had higher hearing thresholds when compared to healthy individuals (group exposed to antiretroviral treatment showed the worst hearing threshold) and seemed to have lower neuroelectric transmission speed along the auditory pathway in the brainstem, subcortical and cortical regions. (C) 2018 Associacao Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial. Published by Elsevier Editora Ltda.
引用
收藏
页码:574 / 582
页数:9
相关论文
共 50 条
  • [1] ALTERATIONS IN HYDRATION IN HIV-INFECTED INDIVIDUALS
    BABAMETO, G
    KOTLER, DP
    BURASTERO, S
    WANG, J
    PIERSON, RN
    CLINICAL RESEARCH, 1994, 42 (02): : A279 - A279
  • [2] Coronary heart disease in HIV-infected individuals: associations with antiretroviral therapy
    Currier, J
    Taylor, A
    Boyd, F
    Kawabata, H
    Maa, J
    Dezii, C
    Burtcel, B
    Hodder, S
    ANTIVIRAL THERAPY, 2002, 7 (03) : L37 - L37
  • [3] The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals
    Ray, Maile
    Logan, Roger
    Sterne, Jonathan A. C.
    Hernandez-Diaz, Sonia
    Robins, James M.
    Sabin, Caroline
    Bansi, Loveleen
    van Sighem, Ard
    de Wolf, Frank
    Costagliola, Dominique
    Lanoy, Emilie
    Bucher, Heiner C.
    von Wyl, Viktor
    Esteve, Anna
    Casabona, Jordi
    del Amo, Julia
    Moreno, Santiago
    Justice, Amy
    Gouler, Joseph
    Lodi, Sara
    Phillips, Andrew
    Seng, Remonie
    Meyer, Laurence
    Perez-Hoyos, Santiago
    de Olalla, Patricia Garcia
    Herman, Miguel A.
    Phillips, A. N.
    Gilson, R.
    Easterbrook, P.
    Fisher, M.
    Gazzard, B.
    Johnson, M.
    Walsh, J.
    Leen, C.
    Orkin, C.
    Anderson, J.
    Pillay, D.
    Delpech, V.
    Schwenk, A.
    Dunn, D.
    Gompels, M.
    Hill, T.
    Porter, K.
    Babiker, A.
    Sabin, C.
    AIDS, 2010, 24 (01) : 123 - 137
  • [4] Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy
    Gerber, MT
    Mondy, KE
    Yarasheski, KE
    Drechsler, H
    Claxton, S
    Stoneman, J
    DeMarco, D
    Powderly, WG
    Tebas, P
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (03) : 419 - 425
  • [5] Kaletra® (lopinavir/ritonavir), an antiretroviral therapy for HIV-infected individuals.
    Sham, HL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U1186 - U1186
  • [6] Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine
    DeSilva, KE
    Le Flore, DB
    Marston, BJ
    Rimland, D
    AIDS, 2001, 15 (10) : 1281 - 1285
  • [7] THE EFFECT OF COMBINED ANTIRETROVIRAL THERAPY ON THE OVERALL MORTALITY OF HIV-INFECTED INDIVIDUALS
    Ray, M.
    Hernan, M. A.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 : S132 - S132
  • [8] Antiretroviral therapy of HIV-infected patients
    Gölz, J
    MEDIZINISCHE WELT, 1999, 50 (06): : 223 - 229
  • [9] Antiretroviral therapy in HIV-infected children
    Fan, Conghai
    Zhang, Fengchao
    Chen, Chao
    MINERVA PEDIATRICA, 2019, 71 (05) : 455 - 460
  • [10] Lipid and glucose alterations in HIV-Infected children beginning or changing antiretroviral therapy
    Chantry, Caroline J.
    Hughes, Michael D.
    Alvero, Carmelita
    Cervia, Joseph S.
    Meyer, William A., III
    Hodge, Janice
    Borum, Peggy
    Moye, Jack, Jr.
    PEDIATRICS, 2008, 122 (01) : E129 - E138